Study to Evaluate Safety and Therapeutic Efficacy of a Nutritional Supplement 'Oncoxin' in Patients With Hepatocellular Carcinoma
To assess therapeutic efficacy and safety of Oncoxin in hepatocellular carcinoma
To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma
patients after administration of Oncoxin
To see if there is reduction tumor size and or number in hepatocellular carcinoma patients
after administration of Oncoxin
To see if there is improvement of quality of life in hepatocellular carcinoma patients after
administration of Oncoxin
To see if there is improved survival in hepatocellular carcinoma patients after
administration of oncoxin
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of patients who have prolonged survival after receiving Oncoxin
To study the number of participants who have prolonged survival after receiving Oncoxin for 24 weeks.
48 weeks
Yes
Mamun A Mahtab, MSc MD FACG
Principal Investigator
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Bangladesh: Directorate of Drug Administration
OP1
NCT01392131
July 2011
July 2013
Name | Location |
---|